About This Project

Our team at iNNO MeDevice aims to improve the prediction of the effects of chemicals and their metabolism on humans with an “Advanced Multi-Organoids-Chip System (AMOS)”, an innovative microfluidic culture and screening system. By merging vascularized human organoids, the AMOS provides a comprehensive preclinical platform that offers systemic-level insights. This breakthrough approach enables more accurate and efficient screening of potential drugs and toxic substances in drug development.

Ask the Scientists

What is the context of this research?

Our project aims to enhance the drug development process by integrating multiple vascularized human organoids with AMOS to offer systemic preclinical insights. This innovative technology regulates the proliferation of pathogenic E. coli and predicts human response to drugs, including Atezolizumab. Systemic interactions play a vital role in organ responses to injury, disease, and therapy, making it essential to comprehend their significance in maintaining tissue homeostasis in both healthy and diseased conditions. The placement of multiple vascularized organoids on AMOS’s microchambers allows for organ cross-communication, enhancing systemic disease modeling and screening. Ultimately, this results in better predictability of human responses to drugs and allows more efficient drug screening.

What is the significance of this project?

Drug development is costly and time-consuming, with a single drug taking up to 15 years and costing over $2.6 billion to bring to market. Inefficiencies arise from reliance on in vitro and animal testing before human trials, which can lead to mismatches between drug efficacy and toxicity in animal models and humans. AMOS technology improves drug development by predicting human response to drugs, including Atezolizumab, and regulating bacterial proliferation, such as pathogenic E. coli, long-term. Our AMOS enables us to forecast the efficacy and toxicity of drug candidates, with superior predictive power towards clinical trials. AMOS reduces drug development costs and timelines by accurately predicting human response to drugs, preventing toxic drugs from advancing through clinical trials.

What are the goals of the project?

Our team construct an integrated AMOS that allows access to the lumen and mucus of multiple human organs at their smallest biological scale to model host-microorganism interactions.

The objectives of this project are: First, we will create an integrated AMOS by 3D printing technology. We will validate AMOS by testing peristaltic motions with FITC dextran and E. coli on the stage of an upright microscope with a camera. We will compare the AMOS peristaltic motions to those observed in the human body. Additionally, we will validate AMOS by screening an approved drug, such as Atezolizumab, using peristaltic motions. The success criteria for AMOS will be based on its ability to accurately emulate the physiological performance of the human body and its potential for perfect clinical translation.